Literature DB >> 1537904

Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin.

B W Berger1, R C Johnson, C Kodner, L Coleman.   

Abstract

Skin biopsy specimens from the peripheral aspect of erythema migrans lesions (site 1) and from clinically normal perilesional areas (site 2) were compared as sources of Borrelia burgdorferi. This spirochete was isolated from the skin of 18 of 21 (86%) patients with untreated early Lyme disease at one or both biopsy sites. Site 1 specimens were superior to site 2 specimens for the isolation of B. burgdorferi. Site 1 specimens from 18 (86%) patients were culture positive, and site 2 specimens from 12 (57%) patients were culture positive. For patients whose site 2 specimens were culture positive, site 1 specimens were also found to be culture positive. B. burgdorferi was isolated from two patients with atypical lesions and from two patients with erythema migrans lesions that were less than 5 cm in diameter. This study demonstrates that the cultivation of B. burgdorferi from skin biopsy specimens from cutaneous lesions thought to be erythema migrans can be an efficacious procedure for confirming the diagnosis of Lyme disease and that the spirochete is present in clinically normal appearing perilesional skin.

Entities:  

Mesh:

Year:  1992        PMID: 1537904      PMCID: PMC265060          DOI: 10.1128/jcm.30.2.359-361.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Heterogeneity of major proteins in Lyme disease borreliae: a molecular analysis of North American and European isolates.

Authors:  A G Barbour; R A Heiland; T R Howe
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

Review 2.  Lyme disease: recommendations for diagnosis and treatment.

Authors:  D W Rahn; S E Malawista
Journal:  Ann Intern Med       Date:  1991-03-15       Impact factor: 25.391

3.  Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis.

Authors:  J Schmidli; T Hunziker; P Moesli; U B Schaad
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

4.  Biology of Borrelia hermsii in Kelly medium.

Authors:  H G Stoenner
Journal:  Appl Microbiol       Date:  1974-10

Review 5.  Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis).

Authors:  E Asbrink; A Hovmark
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

6.  Erythema chronicum migrans of Lyme disease.

Authors:  B W Berger
Journal:  Arch Dermatol       Date:  1984-08

Review 7.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  1989-08-31       Impact factor: 91.245

8.  Isolation of Borrelia burgdorferi from the blood of seven patients with Lyme disease.

Authors:  R B Nadelman; C S Pavia; L A Magnarelli; G P Wormser
Journal:  Am J Med       Date:  1990-01       Impact factor: 4.965

9.  Cultivation and characterization of spirochetes from cerebrospinal fluid of patients with Lyme borreliosis.

Authors:  M Karlsson; K Hovind-Hougen; B Svenungsson; G Stiernstedt
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

10.  Isolation and cultivation of Lyme disease spirochetes.

Authors:  A G Barbour
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug
View more
  53 in total

1.  Infection rate of Ixodes ricinus ticks with Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto in Slovenia.

Authors:  F Strle; Y Cheng; J A Nelson; M M Picken; J K Bouseman; R N Picken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

2.  The laboratory diagnosis of Lyme borreliosis: Guidelines from the Canadian Public Health Laboratory Network.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

3.  Identification of specific chemoattractants and genetic complementation of a Borrelia burgdorferi chemotaxis mutant: flow cytometry-based capillary tube chemotaxis assay.

Authors:  Richard G Bakker; Chunhao Li; Michael R Miller; Cynthia Cunningham; Nyles W Charon
Journal:  Appl Environ Microbiol       Date:  2006-12-15       Impact factor: 4.792

4.  Novel Borrelia burgdorferi isolates from Ixodes scapularis and Ixodes dentatus ticks feeding on humans.

Authors:  J F Anderson; R A Flavell; L A Magnarelli; S W Barthold; F S Kantor; R Wallich; D H Persing; D Mathiesen; E Fikrig
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Improved serodiagnostic testing for Lyme disease: results of a multicenter serologic evaluation.

Authors:  R B Craven; T J Quan; R E Bailey; R Dattwyler; R W Ryan; L H Sigal; A C Steere; B Sullivan; B J Johnson; D T Dennis; D J Gubler
Journal:  Emerg Infect Dis       Date:  1996 Apr-Jun       Impact factor: 6.883

6.  Binding of human plasminogen to Borrelia burgdorferi.

Authors:  L T Hu; G Perides; R Noring; M S Klempner
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Diagnostic value of PCR for detection of Borrelia burgdorferi in skin biopsy and urine samples from patients with skin borreliosis.

Authors:  S Brettschneider; H Bruckbauer; N Klugbauer; H Hofmann
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

8.  Isolation of Borrelia burgdorferi from biopsy specimens taken from healthy-looking skin of patients with Lyme borreliosis.

Authors:  H Kuiper; A P van Dam; L Spanjaard; B M de Jongh; A Widjojokusumo; T C Ramselaar; I Cairo; K Vos; J Dankert
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

9.  Isolation of Borrelia burgdorferi from saliva of the tick vector, Ixodes scapularis.

Authors:  C Ewing; A Scorpio; D R Nelson; T N Mather
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

10.  A guinea pig model for Lyme disease.

Authors:  S W Sonnesyn; J C Manivel; R C Johnson; J L Goodman
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.